Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Jacobsen22,10.1038/s41598-022-22552-y,Pseudovirus (VSV),41598_2022_22552_MOESM2_ESM.xlsx,None,Ad26.COV2.S,1,1m,Human,Wild Type (B.1),=,20.3,1.0,Beta,80,D80A + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,<,1.0,1.0,>,20.3
Jacobsen22,10.1038/s41598-022-22552-y,Pseudovirus (VSV),41598_2022_22552_MOESM2_ESM.xlsx,None,Ad26.COV2.S,1,1m,Human,Wild Type (B.1),=,18.9,1.0,Beta,80,D80A + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,<,1.0,1.0,>,18.9
Jacobsen22,10.1038/s41598-022-22552-y,Pseudovirus (VSV),41598_2022_22552_MOESM2_ESM.xlsx,None,Ad26.COV2.S,1,1m,Human,Wild Type (B.1),=,14.8,1.0,Beta,80,D80A + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,<,1.0,1.0,>,14.8